4. Legend Biotech Corporation (NASDAQ:LEGN)
Stock Upside: 78.73%
Market Capitalization: $6.24 billion
Number of Hedge Fund Holders: 31
Legend Biotech Corporation (NASDAQ:LEGN) is one of the most promising healthcare stocks according to Wall Street analysts. Legend Biotech Corporation (NASDAQ:LEGN) recently announced the first human proof-of-concept results for LB2501, its experimental next-generation cancer therapy. The company presented the data at the European Hematology Association 2026 Congress.
Legend said LB2501 is designed for patients with B-cell non-Hodgkin lymphoma, a blood cancer affecting white blood cells. It added that LB2501 is different from existing cell therapies because rather than removing a patient’s immune cells, engineering them in a laboratory, and reinfusing them, the treatment delivers genetic instructions directly into the patient’s body via a single intravenous infusion.
The ongoing Phase 1 trial tested two dose levels with six patients each. Data showed that at the lower dose, results were modest, but at the higher dose, all six patients responded and five of them achieved a complete response. The data also showed no serious adverse events or treatment-related deaths reported at the data cutoff, though about two-thirds of patients did experience cytokine release syndrome. This is an immune overreaction that is common with this class of therapy, the company said.
Legend also noted that the modified virus used to deliver the genetic instructions was no longer detected in circulation within 24 hours of infusion. It also left a highly diverse, polyclonal integration pattern, which in plain terms means the reprogramming happened in a broad, distributed way rather than concentrating in specific cells.
Legend Biotech Corporation (NASDAQ:LEGN) is a commercial-stage cell-therapy company. It specializes in the discovery and development of novel cell therapies for oncology and other indications.
